Amaranth Medical raises $20 million in a Series B financing round to help the company chase European regulatory approval for its Fortitude bioresorbable scaffold.
Mountain View, Calif.-based Amaranth Medical announced a $20 million Series B funding round in support of development of the company’s flagship Fortitude bioresorbable scaffold, a device-based treatment for coronary artery disease.
Amaranth plans to use the funds to further progress in clinical trials in hopes of winning CE Mark approval in the European Union, according to a company statement.
